Key result
Early-generation TAVR linked to ~70% higher 10-year mortality vs. SAVR in low-risk AS.
Why the study?
Evidence regarding the long-term advantages of TAVR compared with SAVR for aortic stenosis remains scarce.
Does transcatheter aortic valve replacement (TAVR) with early-generation devices improve 10-year survival compared to surgical aortic valve replacement (SAVR) in low-risk patients (EuroSCORE II < 4 %) with severe aortic stenosis?
Cohort (n=710)
Yes
Does transcatheter aortic valve replacement (TAVR) with early-generation devices improve 10-year survival compared to surgical aortic valve replacement (SAVR) in low-risk patients (EuroSCORE II < 4 %) with severe aortic stenosis?
In a propensity-matched observational study of low-risk aortic stenosis patients (EuroSCORE II < 4 %), early-generation TAVR was associated with significantly lower 10-year survival compared to SAVR (18.2 % vs. 37.0 %, p < 0.001), though repeat aortic valve procedure rates were not significantly different.
Answers are grounded in this paper and cite their sources.
Early-generation TAVR survival data urge caution in low-risk aortic stenosis; leaves open whether newer valves improve long-term outcomes.
Background: The evidence of the long-term advantages of transcatheter aortic valve replacement (TAVR) over surgical aortic valve replacement (SAVR) for aortic stenosis (AS) remains scarce. Methods: Patients with EuroSCORE II < 4 % who underwent TAVR or SAVR for AS from the prospective observational OBSERVANT study were included in this analysis. Ten-year survival was the primary outcome of this analysis. Secondary outcome was repeat procedure on the aortic valve prosthesis. Results: Propensity score matching resulted in 355 matched pairs of patients who underwent TAVR or SAVR. The mean age of SAVR patients was 80.0 ± 5.1 years and that of TAVR patients 80.1 ± 6.4 years (p = 0.81) and the mean EuroSCORE II was 2.5 ± 0.8 % and 2.6 ± 0.8 % (p = 0.60), respectively. Thirty-day mortality was 2.8 % after SAVR and 2.5 % after TAVR (p = 0.82). At 10-year, survival was 37.0 % (95 %CI 32.2-42.5 %) after SAVR and 18.2 % (95 %CI 14.5-22.8 %) after TAVR (Log-rank test, p < 0.001; HR 1.70, 95 %CI 1.42-2.03). Difference in terms of survival between the propensity matched cohorts became significant 3 years after the procedures. Ten-year cumulative incidences of repeat aortic valve procedure were 2.6 % (95 %CI 1.4-5.0 %) after SAVR and 1.1 % (95 %CI 0.4-3.0 %) after TAVR (p = 0.153; SHR 0.43, 95 %CI 0.13-1.41). Conclusions: The results of this prospective observational, non-randomized study showed that 10-year survival of low-risk patients who underwent TAVR with early generation prosthesis devices was lower than SAVR.
No takes yet. Share an insight, caveat, or question.
Biancari et al. (2024) conducted a cohort in Severe aortic stenosis (n=710). Transcatheter aortic valve replacement (TAVR) with early-generation prostheses (CoreValve or Sapien XT) vs. Surgical aortic valve replacement (SAVR) was evaluated on 10-year survival (HR 1.70, 95% CI 1.42-2.03, p=<0.001). TAVR with early-generation devices was associated with lower 10-year survival than SAVR in low-risk aortic stenosis patients.
Synapse has enriched 10 related papers. Consider them for comparative context: